Endocrine Abstracts (2009) 20 P612

Pregnancy occurs rarely in acromegalic patients: although octreotide therapy in pregnancy seems to be feasible and safe, enough information regarding the use of OCT in pregnancy is not available yet

Fatih Kilicli1,2,3,4, Serdal Korkmaz1,2,3,4, Sebila Dokmetas1,2,3,4 & Fettah Acibucu1,2,3,4


1Department of Endocrinology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey; 2Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey; 3Department of Endocrinology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey; 4Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.


The patient who was operated because of pituitary macroadenoma causing acromegaly disease had insufficient suppression respond of growth hormone to postoperative oral glucose tolerance test (OGTT). OCT LAR treatment had been started. On the 15.month of the therapy, the patient presented with failure of menstruation since four months, so pregnancy test was performed and pregnancy was diagnosed. The patient had used OCT LAR during the period without knowing that she was pregnant. After it has been shown with magnetic rezonans imaging (MRI) that the pituitary adenoma did not grow, we stopped the OCT LAR treatment. The patient delivered a healthy newborn girl at the 37. gestational week newborn of 2650 g in weight and 50 cm in length. MRI was used for postpartum macroadenoma assessment and it had not grow during this period. Two months after the delivery, because of insufficient suppression respond of growth hormone to OGTT, OCT LAR treatment was restarted.

We believe that the size of the adenoma must be checked to make a decision in discontinuing or continuing treatment when pregnancy developed in acromegalic patients is the most suitable approach. Furthermore, we advocate that OCT should be discontinued during pregnancy until more safety data are obtained.

Article tools

My recent searches

No recent searches.